Answer seven questions about the last few weeks and see how your current dose is performing, so you walk into your review knowing what to ask.
No assessment yet
Enter the patient's details, then press Review this dose.
Weight loss on a GLP-1 medication is not steady, and a slow month does not always mean the dose is wrong. The checker compares what has actually happened against what the clinical trials saw at your dose, then explains which parts of your answer moved the result.
Four questions are checked before anything is scored. If any one of them applies, it decides the outcome on its own — because in those situations the numbers cannot be read fairly.
These are the average rates recorded in the SURMOUNT trials of tirzepatide, the medicine in Mounjaro. They are averages across thousands of people — an individual week can look nothing like them, which is why the checker looks at several weeks at once.
| Mounjaro dose | Typical weekly loss | Usual range |
|---|---|---|
| 2.5 mg | 0.4 kg | 0.25–0.6 kg |
| 5 mg | 0.5 kg | 0.3–0.7 kg |
| 7.5 mg | 0.55 kg | 0.35–0.75 kg |
| 10 mg | 0.625 kg | 0.4–0.85 kg |
| 12.5 mg | 0.675 kg | 0.45–0.9 kg |
| 15 mg | 0.725 kg | 0.5–0.95 kg |
Only your prescriber can change your dose. This tool helps you describe how you are getting on, so your review is a better conversation. It does not give medical advice — always read the patient information leaflet that comes in your medication box, and speak to your prescriber or pharmacist about anything that concerns you.
Built by the CoolDose teamLast updated
The expected weight-loss rates. The SURMOUNT programme for tirzepatide, the medicine in Mounjaro. Jastreboff AM, Aronne LJ, Ahmad NN, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 2022;387(3):205–216. PubMed
Which doses the trial covered. SURMOUNT-1 reported the 5 mg, 10 mg and 15 mg maintenance doses over 72 weeks. The rates this tool uses for 2.5 mg, 7.5 mg and 12.5 mg are interpolated between them rather than taken from the trial, and 2.5 mg is a titration step not intended to drive weight loss. Treat the figures for those three as a guide.
Why Wegovy is not available yet. Those rates are tirzepatide rates. Semaglutide was studied in a separate programme and the two are not directly comparable, so there is nothing to carry across. Rather than score Wegovy against numbers we do not have, that path is switched off until the semaglutide figures are supplied.
The Mounjaro dose ladder and maximum dose. The Summary of Product Characteristics on the electronic medicines compendium. Always read the leaflet in your own box, which is the version that applies to you. medicines.org.uk
Tirzepatide in weight management. NICE technology appraisal TA1026, tirzepatide for managing overweight and obesity. nice.org.uk
Semaglutide in weight management. NICE technology appraisal TA875, semaglutide for managing overweight and obesity. nice.org.uk
What this tool is not. Only your prescriber can change your dose. This is a way to describe how you have been getting on so your review is a better conversation, not a recommendation to act on by yourself. nhs.uk
It applies a fixed scoring algorithm to a patient's response at their current dose and suggests whether to increase, maintain or decrease. It supports a pharmacist's judgement — it does not replace it.
The SURMOUNT programme for tirzepatide (Mounjaro). Each dose has a target kg-per-week figure, which is then adjusted for the patient's adherence before being compared with their actual rate.
Four safety checks run first: already at the maximum dose, severe side effects, adherence under 60%, or fewer than four weeks at the current dose. Any one of them decides the outcome on its own, because the response cannot be fairly assessed.
No. Only your prescriber can change your dose. This is a way to describe how the last few weeks have actually gone — weight change, side effects, appetite control — so your next review is a better conversation. Take the result with you rather than acting on it, and read the patient information leaflet in your medication box, which is the version that applies to you.
The hours of appetite control reported for each of the seven days are summed and divided by 168, the number of hours in a week.